Traws Pharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Traws Pharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $2.79M | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | $226.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $226.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $226.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $226.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $231.0K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $2.18M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $1.23M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $787.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.55M | Mar 16, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $9.17M | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | ($166.52M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($18.95M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($18.96M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($16.16M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($25.16M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($21.50M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($20.57M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($24.09M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($19.67M) | Mar 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | ($17.88M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | ($142.37M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($20.30M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($19.63M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($16.50M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($24.99M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($21.70M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($23.28M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($25.74M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($23.70M) | Mar 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $11.43M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $11.41M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.30M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $16.90M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $15.54M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $16.92M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $19.12M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $20.07M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $25.90M | Mar 29, 2017 |
| FY2014 | Dec 31, 2014 | $10.39M | Mar 30, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | ($18.19M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | ($29.79M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($17.93M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($16.29M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.49M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($23.08M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($20.83M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($22.70M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($23.82M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($15.81M) | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $14.0K | Mar 31, 2025 |
| FY2021 | Dec 31, 2020 | $15.0K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $55.0K | Mar 18, 2021 |
| FY2015 | Dec 31, 2014 | $228.0K | Mar 28, 2016 |
| FY2014 | Dec 31, 2013 | $609.0K | Mar 30, 2015 |
| FY2014 | Dec 31, 2012 | $279.0K | Mar 30, 2015 |
| FY2013 | Dec 31, 2011 | $256.0K | Mar 20, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $10.62M | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | $24.96M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $22.68M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $39.37M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $55.48M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $19.99M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $23.67M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $17.92M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $4.98M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $23.23M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | $11.25M | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | $56.59M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $12.01M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.06M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.36M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $13.81M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $12.10M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $12.54M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $15.84M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $18.11M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $11.57M | Mar 27, 2020 |
| FY2019 | Dec 31, 2018 | $5.39M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($11.69M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.30M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $10.01M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $22.75M | Mar 28, 2016 |
| FY2014 | Dec 31, 2013 | $80.41M | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | ($158.31M) | Mar 20, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | ($639.98M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | ($649.15M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($482.63M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($463.68M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($444.72M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($428.56M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($403.40M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($381.90M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($362.32M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($338.22M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $20.56M | Apr 1, 2024 |
| FY2022 | Dec 31, 2022 | $38.52M | Mar 30, 2023 |
| FY2016 | Dec 31, 2016 | $21.40M | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | $19.80M | Mar 29, 2017 |
| FY2016 | Dec 31, 2014 | $43.58M | Mar 29, 2017 |
| FY2015 | Dec 31, 2013 | $60.01M | Mar 28, 2016 |
| FY2014 | Dec 31, 2012 | $81.53M | Mar 30, 2015 |
| FY2014 | Dec 31, 2011 | $2.71M | Mar 30, 2015 |
| FY2013 | Dec 31, 2010 | $7.34M | Mar 20, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | (35) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (22) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 21, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | (35) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (22) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 21, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2025 | 9.07M | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | 3.65M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 840,251 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 20.93M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 20.90M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 12.40M | Mar 21, 2022 |
| FY2021 | Jul 9, 2020 | 11.61M | Mar 21, 2022 |
| FY2019 | Feb 29, 2020 | 167.26M | Mar 27, 2020 |
| FY2020 | Dec 31, 2019 | 111.17M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 5.67M | Mar 27, 2020 |